Buy Rating Maintained on Lipocine Inc. (LPCN) as Target Climbs to $15
On January 21, H.C. Wainwright raised its price target on Lipocine Inc.
Lipocine Inc. (LPCN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Ikarian Capital Neil Shahrestani | 508,556 | $4,063,362 | +155% | 0.33% |
| 2. | Squadron Capital Management William Blank | 450,000 | $3,595,500 | -16% | 1.32% |
| 3. | Eversept Partners Kamran Moghtaderi | 294,989 | $2,356,962 | 0.12% | |
| 4. | AIGH Investment Partners Orin Hirschman | 200,000 | $1,598,000 | 0.22% | |
| 5. | StemPoint Capital Michelle Ross | 160,420 | $1,281,756 | 0.24% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.03 | 40,000 | $81,200.00 | 203,797 | 2026-04-07 | Filing | |
| $2.05 | 123,000 | $252,150.00 | 163,797 | 2026-04-06 | Filing | |
| $2.03 | 25,000 | $50,750.00 | 160,679 | 2026-04-06 | Filing | |
| $2.02 | 25,000 | $50,500.00 | 135,679 | 2026-04-02 | Filing | |
| $5.03 | 8,706 | $43,791.18 | 107,418 | 2023-05-25 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.35 | 5,000 | $6,767.00 | 693,548 | 2020-12-31 | Filing | |
| $1.35 | 1,700 | $2,286.50 | 698,548 | 2020-12-31 | Filing | |
| $1.35 | 15,000 | $20,250.00 | 1,228,090 | 2020-12-16 | Filing | |
| $1.35 | 8,437 | $11,389.95 | 194,504 | 2020-12-16 | Filing | |
| $1.57 | 43,500 | $68,134.05 | 1,075,112 | 2020-12-04 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 221,616 | $1,770,712 | 0.71% | |
| 2. | 200,668 | $1,603,337 | 0% | |
| 3. | 140,487 | $1,122,491 | 0.01% | |
| 4. | 124,942 | $998,287 | 0.31% | |
| 5. | 89,272 | $713,283 | 0% |
News See All
10 Best Long Term Healthcare Stocks to Buy
Investing in healthcare stocks offers a combination of defensive stability and long-term growth potential, supported by consistent demand for medical services, pharmaceuticals, and healthcare technologies...
5 Best Nano-Cap Stocks To Buy For 2022
CPS Technologies Corporation (NASDAQ:CPSH) is a leading provider of advanced material solutions for the transportation, automotive, energy, computing, telecommunication, aerospace, defense, and oil & ...
Here is What Hedge Funds Think About Lipocine Inc (LPCN)
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios.
Hedge Funds Cashing Out Of Lipocine Inc (LPCN)
In this article we will check out the progression of hedge fund sentiment towards Lipocine Inc (NASDAQ:LPCN) and determine whether it is a good investment right now.
Is Lipocine Inc (LPCN) Going To Burn These Hedge Funds ?
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns.
Market Movers: Delta Air Lines, Inc. (DAL), Lipocine Inc (LPCN), Moneygram International Inc (MGI) and More
What happened: Shares of Helios and Matheson Analytics (NASDAQ:HMNY), best known recently as the majority owner of the MoviePass service that exploded in popularity late last year, have plunged today.
Here's Why Lipocine Inc. (LPCN), Zillow Group Inc. (ZG) and Three Other Stocks Are Gaining Ground Today
The US stock market is trading in negative territory following jobs data that showed that the US economy added 156,000 jobs in September, slightly lower than expected, while the unemployment rate inched...
InterContinental Hotels (IHG), First NBC Bank (FNBC) & More: Afternoon Movers Rocking the Market
The markets opened on a negative note today and have maintained that trend into late-afternoon trading.
Deconstructing the Lipocine Inc (LPCN) Complete Response Letter
Lipocine Inc (NASDAQ:LPCN) just picked up a complete response letter (CRL) from the FDA, concerning its oral testosterone candidate, LPCN 1021.
Hedge Fund Resource Center